Stockscreener 앱 받기
4.9345
2.18%
-0.1155
전일 마감가:
$5.05
열려 있는:
$4.98
하루 거래량:
470.95K
Relative Volume:
0.54
시가총액:
$1.67B
수익:
$563.46M
순이익/손실:
$27.92M
주가수익비율:
51.19
EPS:
0.0964
순현금흐름:
$-146.33M
1주 성능:
+23.81%
1개월 성능:
+61.44%
6개월 성능:
+18.75%
1년 성능:
-39.16%
1일 변동 폭
$4.782
$4.98
1주일 범위
$3.75
$5.39
52주 변동 폭
$2.94
$9.25
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
4.945 | 1.44B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
18.23 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.21 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.23 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.10 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
515.60 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-11-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey
Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media
Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha
Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma
Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci
Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan
Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com
Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com
Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan
Alvotech Q2 2026 Earnings Call Transcript - Sahm
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st
Alvotech Files H1 2026 Results and Schedules Business Update Call - The Globe and Mail
Alvotech holds rating despite H1 2026 earnings miss and FDA delays, eyes multiple biosimilar approvals by Q4 2026. - Pluang
Alvotech earnings missed by $0.02, revenue fell short of estimates - Investing.com India
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts (ALVO) - Seeking Alpha
Alvotech (NASDAQ:ALVO) Trading 6.8% HigherHere's What Happened - MarketBeat
Alvotech Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Alvotech misses Q2 2026 estimates as revenue stalls - Investing.com
ALVO: Revenue and margins set to rebound in H2 as supply normalizes and portfolio expands - TradingView
Alvotech Q2 2026 Earnings Call Summary - Yahoo Finance
Alvotech Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Alvotech 1H Adjusted EBITDA $46.9 M >ALVO - Moomoo
Alvotech (ALVO) reports Q2 loss, beats revenue estimates - FXStreet
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Iceland's Alvotech H1 revenue falls 31% on manufacturing program - TradingView
Alvotech (NASDAQ:ALVO) Releases Earnings Results, Misses Estimates By $0.17 EPS - MarketBeat
ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Quiver Quantitative
Alvotech Q2 Results: EPS Misses Estimate, Sales Fall 39% YoY - scanx.trade
Alvotech H1 Results: Revenue falls 31%, EBITDA down 13% - scanx.trade
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update - The Manila Times
Alvotech affirms FY26 sales guidance of $650M-$700M - scanx.trade
ALVO: Revenue and EBITDA fell in H1 2026, but outlook is strong as manufacturing recovers - TradingView
Alvotech H1 Reports Product Revenue USD 211.9 Million - TradingView
Alvotech (ALVO) raises $165M amid revenue drop and $72M interest hit - Stock Titan
Alvotech Announces Financial Results for the - Moomoo
Alvotech raises about $165 million as FDA decisions are expected in Q4 - Stock Titan
Alvotech earnings on deck as FDA biosimilar decisions loom By Investing.com - Investing.com India
Alvotech earnings on deck as FDA biosimilar decisions loom - Investing.com
Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 461% Upside - Yahoo Finance
Alvotech Hires CGCN Group on Pharma Tariffs - Legis1
Earnings To Watch: Alvotech (ALVO) Q2 2026 -- GF Value Sees 471% Upside - Yahoo Finance
ALVO Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Alvotech (NASDAQ:ALVO) Shares Down 6.7%What's Next? - MarketBeat
Alvotech SA expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Long term debt to total equity ratio of Alvotech Swedish Depository Receipt Repr 1 Sh – TURQUOISE:ALVOS - TradingView
Alvotech to Report Financial Results for H1 2026 - 富途牛牛
Alvotech (Z45) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (Z45) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Alvotech (Z45) Q2 2025 Earnings ReportResults, Call & Slides - tipranks.com
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.33%
0.33%
자본화:
|
볼륨(24시간):